Search Our Scientific Publications & Authors

J Allergy Clin Immunol Pract 2020 May 22. Epub 2020 May 22.

Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado. Electronic address:

In early 2020, the first US and Canadian cases of the novel SARS-CoV-2 infection were detected. In the ensuing months, there has been rapid spread of the infection. In March 2020, in response to the virus, state/provincial and local governments instituted shelter-in-place orders, and non-essential ambulatory care was significantly curtailed, including allergy/immunology services. Read More

Acta Derm Venereol 2020 May 25. Epub 2020 May 25.

Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 812-8582 Fukuoka, Japan. E-mail:

The Patient-Oriented Eczema Measure (POEM, 0-28 points) is a self-assessed, repeatable measurement tool for measuring atopic dermatitis (AD) severity. How-ever, whether POEM score is influenced by allergic comorbidities and whether POEM's severity banding is applicable in web-based surveys for AD remain unclear. A web-based questionnaire survey was conducted in 329 patients with AD. Read More

Acta Derm Venereol 2020 May 25. Epub 2020 May 25.

Department of Dermatology and Venereology, University Hospital of Brest, FR-29200 Brest, France. E-mail:

The prevalence of psychological disorders in patients with common skin diseases was assessed in a large representative sample of the French adult population. General health, as measured by the EQ5D score, was significantly lower if patients reported having rosacea, atopic dermatitis, urticaria, fungal infections, psoriasis or acne. The proportions of participants reporting being extremely anxious or depressed were higher in those who reported having rosacea, atopic dermatitis or contact dermatitis. Read More

Acta Derm Venereol 2020 May 25. Epub 2020 May 25.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, ul. Chalubinskiego 1, PL-50-368 Wrocław, Poland. E-mail:

Little is known about itch related to the use of face masks. This internet survey study investigated the prevalence, intensity and clinical characteristics of itch related to the use of face masks by the general public during the COVID-19 pandemic. A total of 2,315 replies were received, of which 2,307 were included in the final analysis. Read More

J Cutan Med Surg 2020 May 25:1203475420929920. Epub 2020 May 25.

7938 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.

Rev Alerg Mex 2020 Jan-Mar;67(1):9-18

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Hospital Regional Lic. Adolfo López Mateos, Servicio de Dermatología, Ciudad de México, México.

Background: In Mexico, the economic burden of medical care for patients with atopic dermatitis is unknown.

Objective: To determine the annual direct medical costs of the treatment for patients with moderate to severe atopic dermatitis who receive medical attention at "Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado" (Institute for Social Security and Social Services for State Workers, better known as ISSSTE), as well as the main variables associated with it.

Methods: A multicenter, retrospective cohort study. Read More

Med Hypotheses 2020 May 19;143:109852. Epub 2020 May 19.

Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy. Electronic address:

J Am Acad Dermatol 2020 May 21. Epub 2020 May 21.

Dermavant Sciences, Inc., Durham, NC, USA.

Background: Tapinarof cream is a topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for treatment of psoriasis and atopic dermatitis.

Methods: In a phase IIb, double-blind, vehicle-controlled study, adults with plaque psoriasis were randomized to tapinarof cream 0.5% or 1% once (QD) or twice daily (BID) or vehicle QD or BID for 12 weeks with 4-week follow-up. Read More

Allergol Immunopathol (Madr) 2020 May 20. Epub 2020 May 20.

Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

Objective: To assess the Quality of Life (QoL) of children with Atopic Dermatitis (AD) and their families and the impact of the mothers' illness perceptions on the family QoL.

Materials And Methods: Seventy-five children with AD (54 infants and 21 children) and their mothers participated in the study. The following questionnaires were administrated: 1. Read More

Ann Allergy Asthma Immunol 2020 May 20. Epub 2020 May 20.

Department of Pediatrics, National Jewish Health, Denver, CO 80206.

Adv Exp Med Biol 2020 ;1253:107-140

Department of Dermatology, Peking University People's Hospital, Beijing, China.

Atopic Dermatitis (AD) is a common inflammatory disease with a genetic background. The prevalence of AD has been increasing in many countries. AD patients often have manifestations of pruritus, generalized skin dryness, and eczematous lesions. Read More

J Cutan Med Surg 2020 May 22:1203475420928907. Epub 2020 May 22.

7938 12365 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.

Background: Systemic therapy for atopic dermatitis (AD) has been challenging with limited safe and efficacious long-term treatment options. In 2017, dupilumab was approved in the United States, Europe, and Canada as the first targeted therapy for patients with moderate-to-severe AD. Despite promising efficacy and safety results in clinical trials, our understanding of dupilumab in clinical practice remains limited with few studies outside clinical trials in literature. Read More

Int J Dermatol 2020 May 22. Epub 2020 May 22.

Translational Research in Inflammation and Immunology Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases and is caused by multiple factors including genetic factors, skin barrier defects, host immune responses, allergen sensitivity, environmental effects, and infections. Commonly, bacterial and viral infections are present in the eczematous lesions of AD patients and clearly aggravate the symptoms. However, studies of fungal infections in AD are limited in spite of the fact that there are reports showing that Malassezia, Candida, and some dermatophytes can affect the symptoms of AD. Read More

J Dermatol 2020 May 22. Epub 2020 May 22.

Laboratory of Cutaneous Aging and Hair Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.

Previous studies suggest an association between atopic dermatitis (AD) and exposure to microorganisms and antibiotics. However, these studies have limitations, and the sole influence on the development of AD was elusive. We performed a nationwide population-based case-control study in a Korean population to investigate the association between AD and early-life infection or antibiotic exposure. Read More

Am J Clin Dermatol 2020 May 21. Epub 2020 May 21.

Eczema and Skin Barrier Research Program, Dermatology Division, Department of Medicine, University of Arizona, 7165 N Pima Canyon Drive, Tucson, AZ, 85718, USA.

Background: Clothing fabrics interact closely with the skin to shape our cutaneous microenvironment. Cotton and silk have been traditionally recommended for patients with atopic dermatitis because of reported patient comfort. New synthetic fabrics combine anti-microbial, anti-inflammatory, moisture-wicking, and soothing properties that may augment conventional management strategies in atopic patients. Read More

Sci Rep 2020 May 21;10(1):8417. Epub 2020 May 21.

Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.

The main factors involved in the pathogenesis of atopic dermatitis (AD) are skin barrier abnormality, allergy/immunology, and pruritus. Considering how oxidative stress influences these factors, antioxidant agents may be effective candidates in the treatment of AD. To evaluate the effect of Caffeoyl-Pro-His amide (CA-PH), an antioxidant agent, on 2,4-dinitrochlorobenzene (DNCB)-induced AD-like phenotypes in BALB/c mice. Read More

J Am Acad Dermatol 2020 May 18. Epub 2020 May 18.

Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.

J Allergy Clin Immunol 2020 May 18. Epub 2020 May 18.

Département des sciences fondamentales, Université du Québec à Chicoutimi, Saguenay, Quebec, Canada; Centre intersectoriel en santé durable, Université du Québec à Chicoutimi, Saguenay, Quebec, Canada; Department of Pediatrics, Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, Quebec, Canada. Electronic address:

Capsule Summary: To benefit from early and simple interventions that were prove efficient to prevent the atopic march, this study proposes a polygenic risk score having an area under the curve of 88% to identify high-risk children. Read More

J Allergy Clin Immunol 2020 May 18. Epub 2020 May 18.

Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany. Electronic address:

Ocul Surf 2020 May 18. Epub 2020 May 18.

The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:

Dupilumab is the first US FDA approved biologic for treatment of atopic dermatitis. It is a human monoclonal antibody which blocks the shared receptor component, the interleukin (IL)-4α subunit, of IL-4 and IL-13 signaling pathways. Occurrence of "conjunctivitis", mostly in atopic dermatitis trials, has been the main side effect reported thus far. Read More

G Ital Dermatol Venereol 2020 May 21. Epub 2020 May 21.

Dermatology Unit, Catholic University of Rome, and Fondazione Policlinico A. Gemelli - IRCCS, Rome, Italy.

Atopic dermatitis (AD) is a chronic inflammatory disease with increasing global incidence, which has a multifactorial pathogenesis and a variable expressivity. Clinical features of AD are different in adults compared to children, but it is well recognized the substantial impact of the disease on patients' quality of life at any age. Indeed, little is known about AD in adolescence, a period of life generally associated with high psychological burden and vulnerability to depression. Read More

Int J Mol Sci 2020 May 19;21(10). Epub 2020 May 19.

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31-98166 Messina, Italy.

Atopic dermatitis (AD) is a chronic inflammatory disease of the skin, characterized by dryness and more or less severe itching. The etiology of AD is complex and has not been fully clarified, involving genetic susceptibility, immunological abnormalities, epidermal barrier dysfunction, and environmental factors. Xyloglucan (XG) and pea protein (PP) are two compounds of natural origin characterized by the ability to create a physical barrier that protects mucosae membranes, reducing inflammation. Read More

Biomolecules 2020 May 19;10(5). Epub 2020 May 19.

College of Pharmacy, Keimyung University, Daegu 42601, Korea.

While liquiritigenin, isolated from , is known to possess anti-inflammatory activities, it still remains to be known whether liquiritigenin has a suppressive effect on T cell activation and T cell-mediated disease. Here, we used Jurkat T cells to explore an underlying mechanism of pre-treatment with liquiritigenin in activated T cell in vitro and used atopic dermatitis (AD) in vivo to confirm it. We found liquiritigenin blocks IL-2 and CD69 expression from activated T cells by PMA/A23187 or anti-CD3/CD28 antibodies. Read More

J Dermatolog Treat 2020 May 21:1-9. Epub 2020 May 21.

Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy.

The long-term efficacy and safety of dupilumab has been demonstrated in clinical trials and only in few real-world studies. We conducted an extension analysis from a previous 16-week study on 109 adult patients affected by moderate-to-severe atopic dermatitis treated with dupilumab. Eczema-Area-and-Severity-Index (EASI), itch numerical-rating-score (itch-NRS), Dermatology-Life-Quality-Index (DLQI) scores, drug survival rate and occurrence of adverse events after 24 and 48 weeks of dupilumab treatment were retrospectively collected. Read More

Clin Exp Allergy 2020 May 20. Epub 2020 May 20.

School of Community Health Sciences, University of Nevada, Reno, NV, USA.

Background: Cesarean delivery (C-section) may disrupt maternal-infant microbial transfer and alter immune system development and subsequent risk for atopic dermatitis.

Objective: Investigate the association between C-section and atopic dermatitis by age four and examine potential sources of bias in the relationship in a large cohort study.

Methods: Maternal and child information was collected through Kaiser Permanente Northern California's (KPNC) integrated healthcare system. Read More

Dermatol Ther (Heidelb) 2020 May 20. Epub 2020 May 20.

Global Biometrics and Data Management (Statistics), Pfizer Inc., Groton, USA.

Introduction: There is a need to compare efficacy and safety profiles of crisaborole ointment, 2%, versus other topical treatments across randomized clinical trials (RCTs). We performed this review/network meta-analysis to evaluate the comparative efficacy and safety of crisaborole versus other topical pharmacologic therapies for mild-to-moderate atopic dermatitis (AD) among patients aged ≥ 2 years.

Methods: Searches were conducted in MEDLINE, Embase, the Cochrane Collection Central Register of Clinical Trials, and the Database of Abstracts of Reviews of Effects using Ovid to identify English language articles reporting RCTs of topical anti-inflammatory agents in patients aged ≥ 2 years with mild-to-moderate AD published between inception and 10 March 2020. Read More

Arerugi 2020 ;69(3):218-219

Arerugi 2020 ;69(3):213-217

Department of Pediatrics, National Hospital Organization Fukuoka National Hospital.

Background: Prurigo nodularis is a chronic disease characterized by a hard dome-like or wart-like nodule which is solitary and does not fuse. Prurigo nodularis presents as one of the symptoms of atopic Dermatitis (AD).

Cases: We present three cases of AD children with intractable prurigo nodularis. Read More

Arerugi 2020 ;69(3):174-183

Clinical Development & Regulatory Strategy Center, Teikoku Seiyaku CO LTD.

Background: Histamine H1 receptor antagonists (antihistamines) are recommended as adjunctive therapy for atopic dermatitis (AD). However, their long-term usefulness and the effect of updosing have not been clarified.

Purpose: To analyzed the long-term usefulness and the effect of updosing of rupatadine, a second generation antihistamine, for patients with AD. Read More

J Allergy Clin Immunol 2020 May 17. Epub 2020 May 17.

Skin Research Group, School of Medicine, University of Dundee, Dundee, UK; Department of Dermatology, Ninewells Hospital and Medical School, Dundee, UK. Electronic address:

J Clin Pharmacol 2020 May 20. Epub 2020 May 20.

Pfizer Inc, Groton, Connecticut, USA.

Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Results from 2 randomized, double-blind, vehicle-controlled phase 3 studies showed that twice-daily crisaborole in children and adults with mild to moderate atopic dermatitis was efficacious and well tolerated. Initial pharmacokinetics (PK) studies of crisaborole indicated absorption with measurable systemic levels of crisaborole. Read More

J Dermatolog Treat 2020 May 20:1-13. Epub 2020 May 20.

Department of Pediatric Pulmonology and Allergy, The Medical University of Warsaw, Żwirki i Wigury 63A, PL-02-091 Warsaw, Poland.

Atopic dermatitis is a chronic disease affecting up to 20% of children. The growing concern relating to the skin barrier dysfunction resulted in development of dermo-cosmetics market. The selection of best emollient is usually based on "trial and error". Read More

Proc Natl Acad Sci U S A 2020 May 19. Epub 2020 May 19.

Genentech, South San Francisco, CA 94080;

PD-1 and PD-L1 act to restrict T cell responses in cancer and contribute to self-tolerance. Consistent with this role, PD-1 checkpoint inhibitors have been associated with immune-related adverse events (irAEs), immune toxicities thought to be autoimmune in origin. Analyses of dermatological irAEs have identified an association with improved overall survival (OS) following anti-PD-(L)1 therapy, but the factors that contribute to this relationship are poorly understood. Read More

J Med Microbiol 2020 May 20. Epub 2020 May 20.

Laboratório de Infecção Hospitalar, Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Atopic dermatitis (AD) is a chronic skin disease that affects up to 20 % of the paediatric population worldwide. colonizes anterior nares and can be transmitted in the home environment, aggravating AD. This study aimed to detect from nares of AD patients and their family contacts, as well as to evaluate the antimicrobial resistance, virulence and clonality of these isolates. Read More

J Am Acad Dermatol 2020 May 16. Epub 2020 May 16.

Departments of Medical Social Sciences, Preventive Medicine, Neurology, and Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Background: Atopic dermatitis (AD) is associated with itch, pain, and sleep disturbance, all of which may contribute toward cognitive dysfunction.

Objective: To determine the relationship of AD severity and cognitive function in adults.

Methods: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n=386). Read More

J Invest Dermatol 2020 May 16. Epub 2020 May 16.

Novan, Inc., Morrisville, NC. Electronic address:

J Allergy Clin Immunol 2020 May 16. Epub 2020 May 16.

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York; Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York; The Laboratory for Investigative Dermatology, The Rockefeller University, New York. Electronic address:

Capsule Summary: In a clinical trial of moderate-to-severe atopic dermatitis/AD patients treated with anti IL-17mAb/secukinumab, no significant clinical or molecular improvements were seen, even among disease subtypes with high Th-17-skewing (intrinsic/Asian AD). Read More

Drugs Context 2020 4;9. Epub 2020 May 4.

Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.

Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL-13 are key cytokines in the immunopathogenesis of AD. New emerging agents include dupilumab, a fully human monoclonal antibody directed against the IL-4 receptor a subunit that blocks both IL-4 and IL-13 signaling and has shown significant efficacy in patients with moderate-to-severe AD. Read More

Allergy 2020 Apr 23. Epub 2020 Apr 23.

Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.

Background: Dupilumab is an anti-IL-4Rα antibody used in the treatment of patients with moderate-to-severe atopic dermatitis (msAD). This study explored the potential benefit of dupilumab in perennial allergic rhinoconjunctivitis (PAR) and perennial allergic asthma (PAA) caused by indoor allergens in adults with msAD.

Methods: This multicentric, prospective, observational, real-life study included adult patients with msAD who had been treated with dupilumab in 16 Italian care centres. Read More

Acta Derm Venereol 2020 May 19. Epub 2020 May 19.

Department of Dermatology, University Hospital of Brest, FR-29200 Brest, France.

Pruritus in atopic dermatitis has been studied extensively; however, evaluation of skin pain has been very limited. The aim of this study was to evaluate the presence, frequency and characteristics of skin pain in patients with atopic dermatitis. A survey was conducted of a representative sample of 5,000 18-80-year-old individuals selected from the French population according to sex, age, geographical area and socioprofessional status. Read More

Biomed Pharmacother 2020 May 16:110197. Epub 2020 May 16.

College of Pharmacy, Dankook University, Dandae-ro 119, Dongnam, Cheonan, Chungnam, 31116, Republic of Korea. Electronic address:

Int Arch Allergy Immunol 2020 May 18:1-5. Epub 2020 May 18.

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland,

Background: An increased expression of interleukin (IL)-15, a cytokine with a key role in stimulating innate and adaptive immune cells, such as dendritic cells (DC), natural killer cells, and T cells, has been observed in infectious and inflammatory diseases, including autoimmune diseases as well as cancer. Atopic dermatitis (AD) is a common inflammatory skin disease characterized by a type 2 immune response.

Objective: To explore the expression of IL-15 and its pattern in AD skin. Read More

J Dermatolog Treat 2020 May 18:1-5. Epub 2020 May 18.

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

J Korean Med Sci 2020 May 18;35(19):e122. Epub 2020 May 18.

Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Chaga mushrooms are widely used in folk remedies and in alternative medicine. Contrary to many beneficial effects, its adverse effect is rarely reported. We here report a case of end-stage renal disease after long-term taking Chaga mushroom. Read More

Acta Derm Venereol 2020 May 15. Epub 2020 May 15.

Department of Dermatology, College of Medicine, Chosun University, 61453 Gwangju, Korea.

Atopic dermatitis (AD) is a chronic, inflammatory cutaneous disease that is characterized by complex immune dysregulation and skin barrier dysfunction with a wide variety of clinical phenotypes. Until recently, conventional therapeutic modalities for AD remained rather non-specific despite AD's complex etiology. Failing to take into account the underlying inflammatory pathways led to treatments with inadequate efficacy or unacceptable long-term toxicities. Read More

Acta Derm Venereol 2020 May 15. Epub 2020 May 15.

Centre of Evidence-Based Dermatology, Queen's Medical Centre, University of Nottingham, NG7 2UH Nottingham, United Kingdom. E-mail:

Despite advances in atopic dermatitis (AD) treatments, research into AD prevention has been slow. Systematic reviews of prevention strategies promoting exclusive and prolonged breastfeeding, or interventions that reduce ingested or airborne allergens during pregnancy and after birth have generally not shown convincing benefit. Maternal/infant supplements such as Vitamin D have also not shown any benefit with the possible exception of omega-3 fatty acids. Read More

Acta Derm Venereol 2020 May 15. Epub 2020 May 15.

Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.

Atopic dermatitis is a common inflammatory skin disease with a complex pathogenesis that includes imbalanced immune system signalling, impaired skin barrier and enhanced Staphylococcus aureus skin colonization. The skin bacterial communities are characterized by increasing abundance of S. aureus, leading to reduced diversity compared with the bacterial communities on healthy skin, and increasing disease severity. Read More

Dermatol Ther 2020 May 17:e13606. Epub 2020 May 17.

Department of Dermatology, University Hospital Basel, Switzerland.

Itch is the commonest skin-related symptom, associated with a high psychosocial and economic burden. While the main focus of itch research lies on a few chronic skin diseases, only little is known about the perception of itch, itch-aggravating/-relieving factors and treatment preferences in patients with acute and chronic itch of various etiology. In this cross-sectional study we assessed these aspects in 126 patients (mean age 61. Read More

Pharmacol Res 2020 May 14;158:104878. Epub 2020 May 14.

Pediatric Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address:

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disease, affecting up to 25% of children. Topical corticosteroids (TCS) are currently used as first-line antiinflammatory treatment for AD, due to their overall therapeutic efficacy, and the availability of different potency classes and a wide array of formulations. Therapeutic efficacy of TCS depends upon selecting the appropriate vehicle and potency, and the frequency of application, also taking into account the duration of treatment and patient preferences. Read More

Asian Pac J Allergy Immunol 2020 May 17. Epub 2020 May 17.

Department of Pediatrics, Childhood Asthma Atopy Center, Environmental Health Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Background: Maternal anxiety during pregnancy has been previously reported to be associated with atopic dermatitis (AD) in offspring. The potential mechanism is not yet proven but epigenetic change may be suggested.

Objective: We examined whether maternal anxiety during pregnancy may alter placental DNA methylation, then develop AD in the offspring. Read More